FDA Brief

Warning letters Drugs

FDA warning letter to

Purushothaman Damodara Kumaran, M.D. / Senthil Specialty Hospital

High riskIssued Dec 22, 2025Posted Jan 13Center for Drug Evaluation and Research (CDER)

FDA warned Senthil Specialty Hospital and Dr. Purushothaman Damodara Kumaran about missed safety monitoring in a bioequivalence study of an investigational drug.

What happened

FDA inspected Senthil Specialty Hospital in Pondicherry, Puducherry, India, from January 20 to 24, 2025, as part of its Bioresearch Monitoring Program. FDA found that the clinical investigator did not follow the investigational plan for a clinical in vivo bioequivalence study. For certain subjects, required hematology and pulmonary function safety assessments were not completed after dosing on Day 8, Day 22, and Day 35 in both Period I and Period II.

What FDA found

  1. The investigator failed to ensure the study was conducted according to the investigational plan because required hematology and pulmonary function safety assessments were not completed at protocol-specified times.

    21 CFR 312.60

What FDA wants

Within 15 business days of receipt, notify FDA in writing of actions taken to prevent similar violations in the future, and include reasoning and supporting information if you believe you complied.

Who should pay attention

  • clinical research sites conducting FDA-regulated bioequivalence studies
  • sponsors relying on investigator-site safety data
  • ethics committees overseeing clinical trials

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Jose M. Carpio, M.D.

    FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.

    Medium
  2. Bertrand P. Cole, D.O.

    FDA warns Dr. Bertrand P. Cole that he gave four trial subjects too much drug by not following the study plan.

    High risk
  3. Devalingam Mahalingam, M.D., Ph.D.

    FDA warns clinical investigator Devalingam Mahalingam, M.D., Ph.D. over a 100-fold investigational drug overdose that led to a subject's death.

    High risk
  4. Ralph A. DeFronzo, M.D.

    FDA warns Dr. Ralph A. DeFronzo for enrolling ineligible subjects and failing to promptly report study changes to the IRB.

    High risk